Non-Erosive Reflux Disease (NERD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 Non-Erosive Reflux Disease (NERD) Market Outlook

Thelansis’s “Non-Erosive Reflux Disease (NERD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Non-Erosive Reflux Disease (NERD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Non-Erosive Reflux Disease (NERD) Overview

Non-erosive reflux disease (NERD) represents a specific manifestation within the spectrum of gastroesophageal reflux disease (GERD). It is defined as a subcategory of GERD characterized by the presence of troublesome reflux-related symptoms, all the while showing no signs of mucosal erosions or breaches in the esophagus during routine endoscopy. In clinical practice, patients presenting with reflux symptoms and negative endoscopic findings can be further classified into four categories: (1) acid-reflux-related NERD (marked by increased acid reflux), (2) weakly acid-reflux-related NERD (exhibiting weakly acidic reflux with a positive symptom association, indicative of a hypersensitive esophagus), (3) nonacid-reflux-related NERD (characterized by nonacidic reflux with a positive symptom association), and (4) functional heartburn (where no discernible link exists between symptoms and reflux). Comparatively, NERD patients tend to experience lower levels of acid reflux than patients suffering from erosive esophagitis and Barrett’s esophagus. The differentiation between NERD and erosive esophagitis currently relies on white light endoscopy. At the same time, the distinction between NERD and functional heartburn necessitates pH monitoring, often coupled with impedance measurements to gauge symptom-reflux associations. In general, it is noted that only around 20-30% of NERD patients respond positively to a standard dose of proton pump inhibitors (PPIs).

• In the United States, the estimated prevalence of GERD falls from 18.1% to 27.8%. Approximately half of all adults will report experiencing reflux symptoms at some point. Remarkably, NERD accounts for a significant proportion of all GERD cases, ranging from 50% to 85%.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Non-Erosive Reflux Disease (NERD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034